|
|
Article: ASTELLAS, MEDIVATION TO DEVELOP, COMMERCIALIZE MDV3100 FOR TREATMENT OF PROSTATE CANCER
- Article from:
- US Fed News Service, Including US State News
- Article date:
- November 5, 2009
CopyrightCopyright © HT Media Ltd. All Rights Reserved. Provided by ProQuest LLC. (Hide copyright information)
|
LOS ANGELES, Nov. 4 -- The University of California at Los Angeles issued the following press release:
Astellas Pharma Inc. of Japan and California's Medivation Inc. have announced a global agreement to develop and commercialize MDV3100, a chemical compound developed in UCLA science laboratories that is now Medivation's investigational drug for the treatment of prostate cancer.
MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
Michael Jung, UCLA professor of chemistry and biochemistry and a researcher at UCLA's Jonsson Comprehensive Cancer Center, and his ...